Last updated: February 20, 2026
What is Apixaban and Why Is It Relevant for Investment?
Apixaban is an oral anticoagulant developed by Bristol-Myers Squibb and Pfizer. It is marketed under the brand name Eliquis. Approved by the US Food and Drug Administration (FDA) in 2012, apixaban is used to prevent blood clots in atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), and for postoperative thromboprophylaxis.
The drug competes in a highly lucrative market, estimated globally at around $8 billion in 2022, with projected compound annual growth rate (CAGR) of 6% through 2030. It faces competition from rivaroxaban, dabigatran, and warfarin but maintains a strong market position due to its efficacy and safety profile.
What are the Market Dynamics and Competitive Position of Apixaban?
Market Overview
| Parameter |
Data |
| 2022 Global Market Size |
$8 billion |
| Major Markets |
US, EU, China, Japan |
| Target Indications |
Atrial fibrillation, DVT, PE, postoperative prophylaxis |
| CAGR (2023-2030) |
6% |
Competitive Landscape
| Key Drugs |
Market Share (Est. 2022) |
Development Stage |
Notes |
| Apixaban (Eliquis) |
38% |
Mature |
Leading in atrial fibrillation and DVT/PE indications |
| Rivaroxaban |
30% |
Mature |
Strong second-place, similar indications |
| Dabigatran |
12% |
Mature |
Approved primarily for stroke prevention in AFib |
| Warfarin |
15% |
Generic |
Limited by necessity of monitoring and dietary restrictions |
Key Drivers for Investment
- Demonstrated superior safety profile compared to competitors, especially regarding bleeding risks.
- Expanding indication approvals, including extended use in reduction of risk post-orthopedic surgery.
- Growing prevalence of atrial fibrillation and venous thromboembolism globally.
- Increased adoption by healthcare providers in emerging markets.
How Do the Fundamentals Look for Apixaban?
Patent and Regulatory Data
- Patent expiry for Eliquis is projected for 2030 in the US and EU, after extensions.
- Regulatory approvals span over 100 countries, with recent extensions for stroke prevention in patients with moderate renal impairment.
Revenue and Sales Trends
| Year |
Sales (USD millions) |
Year-over-Year Growth (%) |
| 2020 |
4,200 |
10% |
| 2021 |
4,620 |
10% |
| 2022 |
5,100 |
10.4% |
- Consistent double-digit growth driven by expanding indications and geographic market expansion.
- Key markets include the US (~$2.7 billion), Europe (~$1.7 billion), China (~$400 million).
Cost and Margins
- Manufacturing cost per unit is between $50 and $70, with a gross margin exceeding 85% due to high drug pricing.
- R&D expenses estimated at 10-15% of sales, primarily for new indications and biosimilar competition monitoring.
Financials of Bristol-Myers Squibb (BMS) and Pfizer
| Company |
Revenue from Eliquis (USD millions) |
R&D Investment (USD millions) |
Operating Margin (%) |
| BMS |
60% of oncology and CV franchise |
4,500 (2022) |
33% |
| Pfizer |
75% of CV drug portfolio |
1,200 (2022) |
29% |
Patent Landscape and Biosimilar Threat
- Patent protection until 2030 provides market exclusivity.
- Biosimilar competition is unlikely given the complex nature of apixaban's manufacturing and existing patent extensions.
What Are the Risks and Opportunities?
Risks
- Patent cliff after 2030 could lead to revenue erosion unless new indications are approved.
- Competition from biosimilars or generics may reduce pricing power.
- Regulatory delays or restrictions in emerging markets could limit growth.
- Potential safety concerns could impact regulatory approval or market perception.
Opportunities
- Approval expansion for additional indications, especially in thromboprophylaxis post-orthopedic surgery.
- Increasing shift toward oral anticoagulants over warfarin globally.
- Growth in emerging markets driven by aging populations and increasing cardiovascular disease prevalence.
- Potential for partnership or licensing deals in unpenetrated regions.
What Is the Investment Outlook?
- Apixaban remains a core asset for BMS and Pfizer due to its leading market position and robust revenue growth.
- Revenue is likely to grow at a CAGR of 5-8% through 2025, driven by ongoing market penetration.
- The expiration of patents in 2030 raises risks of revenue decline unless new indications or formulations are approved.
- Stock valuation reflects a premium for strong market share, stable cash flows, and growth potential.
Key Takeaways
- Apixaban is a leading oral anticoagulant with stable revenue streams and expanding indications.
- Market growth is supported by aging populations and the shift from warfarin to direct oral anticoagulants.
- Patent expiry in 2030 presents a risk for revenue decline, contingent on pipeline success.
- Competition from biosimilars remains low due to manufacturing complexity and patent protections.
- Investment hinges on continued market expansion, regulatory approvals, and pipeline development.
FAQs
1. How long will apixaban remain profitable given patent expiry?
Patents expire around 2030 in major markets, but revenue may persist if new indications or formulations are approved and biosimilar competition remains limited.
2. What are the main competitors to apixaban?
Rivaroxaban, dabigatran, and warfarin are primary competitors, with rivaroxaban closest in market share.
3. Are there any recent regulatory issues affecting apixaban?
No significant recent regulatory restrictions; approvals continue to expand, including in emerging markets.
4. What emerging markets offer growth opportunities for apixaban?
China, India, and Southeast Asian countries present expanding markets due to increasing cardiovascular disease prevalence.
5. How do manufacturing costs impact margins?
Manufacturing costs are relatively low ($50–$70 per unit), maintaining gross margins above 85%, supporting pricing power.
References
[1] IQVIA. (2022). Global Market Report: Anticoagulants.
[2] Bristol-Myers Squibb. (2023). Annual Report.
[3] Pfizer. (2023). Annual Report.
[4] U.S. Food and Drug Administration. (2012). Approval for Eliquis.
